EZZ Life Science Holdings Ltd
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consum… Read more
EZZ Life Science Holdings Ltd (EZZ) - Total Assets
Latest total assets as of December 2025: AU$32.60 Million AUD
Based on the latest financial reports, EZZ Life Science Holdings Ltd (EZZ) holds total assets worth AU$32.60 Million AUD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
EZZ Life Science Holdings Ltd - Total Assets Trend (2017–2024)
This chart illustrates how EZZ Life Science Holdings Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
EZZ Life Science Holdings Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
EZZ Life Science Holdings Ltd's total assets of AU$32.60 Million consist of 97.3% current assets and 2.7% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 61.4% |
| Accounts Receivable | AU$4.56 Million | 13.4% |
| Inventory | AU$2.43 Million | 7.2% |
| Property, Plant & Equipment | AU$890.10K | 2.6% |
| Intangible Assets | AU$28.13K | 0.1% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how EZZ Life Science Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EZZ Life Science Holdings Ltd's current assets represent 97.3% of total assets in 2024, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 61.4% of total assets in 2024, down from 100.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 13.4% of total assets.
EZZ Life Science Holdings Ltd Competitors by Total Assets
Key competitors of EZZ Life Science Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
EZZ Life Science Holdings Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - EZZ Life Science Holdings Ltd generates 1.97x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, EZZ Life Science Holdings Ltd generates $ 19.82 in net profit.
EZZ Life Science Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.57 | 5.36 | 2.25 |
| Quick Ratio | 5.80 | 5.08 | 2.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$26.73 Million | AU$ 23.28 Million | AU$ 3.37 Million |
EZZ Life Science Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between EZZ Life Science Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.79 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | 32.9% |
| Total Assets | AU$33.96 Million |
| Market Capitalization | $7.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values EZZ Life Science Holdings Ltd's assets below their book value (0.23 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: EZZ Life Science Holdings Ltd's assets grew by 32.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for EZZ Life Science Holdings Ltd (2017–2024)
The table below shows the annual total assets of EZZ Life Science Holdings Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$33.96 Million | +32.89% |
| 2023-12-31 | AU$25.55 Million | +44.85% |
| 2022-12-31 | AU$17.64 Million | +23.66% |
| 2021-12-31 | AU$14.27 Million | +18.50% |
| 2020-12-31 | AU$12.04 Million | +3.52% |
| 2019-12-31 | AU$11.63 Million | +298.99% |
| 2018-12-31 | AU$2.91 Million | +2914509.00% |
| 2017-12-31 | AU$100.00 | -- |